Knowledge and perception about prostate cancer risks and screening program in Thai male with positive family history of prostate cancer
Keywords:
Knowledge, perception, prostate cancer risks, screening program, family historyAbstract
Purpose: To assess the perception of prostate cancer risk and knowledge of existing prostate cancer screening program in high risk Thai male with familial history of prostate cancer.
Methods: By questionnaire and interviewing Thai male above 40 years old who have family history of prostate cancer (first degree relative of prostate cancer patients).
Results: 62 Thai males, first degree relative of prostate cancer patients with age between 40 to 75 years were enrolled for evaluation of prostate cancer knowledge. Overall 67.75% of them didnût perceived about their risk factors for prostate cancer whereas 56.45% didnût know about existing of prostate cancer screening test. Only 12.9% having been screened for prostate cancer and almost all of them were reported as having PSA test, but not a digital rectal exam. 75.95% of the un-screened patients want to participate in screening program having been informed of their risk of prostate cancer, benefit and harmful of prostate cancer screening.
Conclusion: The results highlight that Thai male with a positive family history of prostate cancer didnût perceived about their risk of prostate cancer and didnût know about existing of prostate cancer screening program. The physician should concern about providing information to this high risk population
References
Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337-47.
Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802.
Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, et al. Family history and prostate cancer risk in Black, White, and Asian Men in the United States and Canada. Am J Epidemiol 1995; 141: 732-40.
Arcangeli CG, Ornstein DK, Keetch DW. Postate-specific antigen as a screening test for prostate cancer: the United States experience. Urol Clin North Am 1997; 24: 299-306.
de Koning HJ, Liem MK, Baan CA. ERSPC. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostat Cancer(ERSPC) trial. Int J Cancer 2002; 98: 268-73.
Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the national cancer institue:history, organization, and status. Control Clin Trials 2000; 21: 251S-72S.
Eeles RA, Dearnaley DP, Ardern-Jones A, Shearer RJ, Easton DF, Ford D, et al: Familial prostate cancer: The evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol 1997; 79 (suppl 1): 8-14.
Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. J Urol 2002; 168: 1983-4.
Bratt O. Hereditary prostate cancer: Clinical aspects. J Urol 2002; 168: 906-13.
Thompson I, Carroll P, Coley C, et al: Prostate-specific antigen (PSA) best practice policy. American Urological Association. Oncology 2000; 14: 267.
Cormier L, Kwan L, Reid K, et al. Knowledge and beliefs among brothers and sons of men with prostate cancer. Urology 2002; 59: 895-900.
Bratt O, Damber JE, Emanuelsson M, Kristoffersson U, Lundgren R, Olsson H, et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer 2000; 36: 235-41.
